Did You Know...
...that power steering was invented by independent inventor Francis W. Davis? As chief engineer in the 1920s of the truck division of the Pierce Arrow Motor Car Company, he saw how hard it was to steer heavy vehicles. So that he would be able to keep the profits from his future invention, Davis left his job, rented a small engineering shop in Waltham, Mass., and developed a hydraulic power steering system that led to power steering.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128626 | ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ANEMIA The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat anemia (e.g., anemia associated with chemotherapy) including persons on a treatment... | 05/24/2012 |
| 20120128627 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules... | 05/24/2012 |
| 20120128625 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.... | 05/24/2012 |
| 20120107267 | INTERLEUKIN-21 VARIANTS HAVING ANTAGONISTIC BINDING TO THE IL-21 RECEPTOR The invention relates to isolated IL-21 variant peptides having antagonistic binding to the common gamma chain (yC) of the IL-21 receptor, to pharmaceutical compositions comprising said peptides and to the use of said peptides in therapy.... | 05/03/2012 |
| 20120107230 | Treatment of Hyperproliferative Diseases with Vinca Alkaloid N-Oxide Analogs The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination ... | 05/03/2012 |
| 20120107269 | THIOPHENE DERIVATIVES Disclosed is a compound of formula (I), wherein
| |
| 20120107270 | Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer This invention relates to the treatment of cancer using anti-ErbB antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.... | 05/03/2012 |
| 20120107366 | Block Copolymer Systems and Their Use in Medical Devices The present disclosure relates to block copolymers, methods for their production, and the use of these copolymers in medical devices. In embodiments, the block copolymers may be used in tissue reinforcement including, for example, in hernia repair. The copolymers posses... | 05/03/2012 |
| 20120107235 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the tre... | 05/03/2012 |
| 20120107237 | ARG-GLY-ASP-CONJUGATED ALPHA-MELANOCYTE STIMULATING HORMONE HYBRID PEPTIDE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME The present invention is directed to novel non-invasive diagnostic and therapeutic tools/compounds comprising a hybride cyclic peptide which utilizes a cyclic peptide chelating group wherein the compound binds to a MSH receptor to image and treat cancers, especially, me... | 05/03/2012 |
| 20120107268 | LYMPH NODE-TARGETING NANOPARTICLES Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1α, IL-10, IL-18, and combinations thereof. Further provided are met... | 05/03/2012 |
| 20120082645 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF The present disclosure provides 2′-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2′-C-methyl-ribofuranosyl cytidine prodrugs, and methods of using 2′-C-methyl-ribofuranosyl... | 04/05/2012 |
| 20120082618 | PROSTATE CANCER DIAGNOSIS AND TREATMENT The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate ... | 04/05/2012 |
| 20120082644 | CYTOKINES AND NEUROANTIGENS FOR TREATMENT OF IMMUNE DISORDERS The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provide... | 04/05/2012 |
| 20120082643 | Compositions and Methods for Modulating a Cytotoxic T Lymphocyte Immune Response The present invention provides compositions and methods for the treatment and prevention of immune disorders.... | 04/05/2012 |
| 20120070405 | Uses of Modified ELR-CXC Chemokine G31P To Treat Cancer Described herein is the use of a modified human chemokine, GS-CXCL8(3-72)K11R/G31P or G31P in the treatment of a number of cancers, including but by no means limited to prostate cancer, liver cancer and melanoma.... | 03/22/2012 |
| 20120070404 | Increasing cancer patient survival time by administration of dithio-containing compounds The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or... | 03/22/2012 |
| 20120070407 | Therapy for Promoting Cell Growth There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells.... | 03/22/2012 |
| 20120070408 | METHODS AND COMPOSITIONS FOR TREATING LUPUS The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and meth... | 03/22/2012 |
| 20120070406 | THERAPEUTIC PROTEIN COMPOSITIONS HAVING REDUCED IMMUNOGENICITY AND/OR IMPROVED EFFICACY The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical compositions of therapeutic proteins and methods of treatment with the same, the c... | 03/22/2012 |
| 20120052044 | USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.... | 03/01/2012 |
| 20120052116 | IMMUNOGENIC EPITOPES OF NGEP ANTIGEN The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid... | 03/01/2012 |
| 20120045413 | Human papilloma virus peptide-specific T-cell response for treatment of warts The inventors have treated human patients for warts by intralesional injection of Candida antigen to induce a delayed-type hypersensitivity response in the patients. This creates an immune response that recognizes the antigens of the human papilloma virus (HPV) f... | 02/23/2012 |
| 20120045487 | MULTIPHASIC MICROFIBERS FOR SPATIALLY GUIDED CELL GROWTH A multiphasic microfiber for a three-dimensional tissue scaffold and/or cellular support is provided in one aspect that includes at least one biocompatible material. The multiphasic microfiber optionally has a first phase and at least one distinct additional phase and i... | 02/23/2012 |
| 20120045394 | HUMAN AND MOUSE TARGETING PEPTIDES IDENTIFIED BY PHAGE DISPLAY The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, incl... | 02/23/2012 |
| 20120039843 | CONJUGATES OF A POLYPEPTIDE AND AN OLIGOSACCHARIDE The present invention relates to conjugates of a polypeptide and an oligosaccharide, wherein the polypeptide is conjugated to at least one oligosaccharide-spacer residue, the oligosaccharide being a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units... | 02/16/2012 |
| 20120039844 | COMPOSITION AND USE OF N-ALPHA-METHYLHISTAMINE DIHYDROCHLORIDE FOR THE REDUCTION OF OXYGEN RADICAL FORMATION An improved composition and method for reducing the formation of oxygen radicals in mononuclear phagocytes is disclosed. Also provided is a method of protecting NK cells from oxidative damage inflicted by radicals produced by mononuclear phagocytes by administering a hi... | 02/16/2012 |
| 20120039797 | Antibody Therapy The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.... | 02/16/2012 |
| 20120039845 | NUCLEOSIDE PRODRUGS AND USES THEREOF Compounds having the formula I or II, wherein R1, R2, B, and V are as defined herein, are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 02/16/2012 | |
| 20120039842 | COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include ... | 02/16/2012 |
| 20120039801 | SPARC binding peptides and uses thereof Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are dis... | 02/16/2012 |
| 20120039840 | Use of IL-27-P28 to antagonize IL-6 mediated signaling Provided are methods increasing, or, alternatively, decreasing IL-6 and/or gp130-mediated signaling in mammalian subjects using p28. Methods of preventing and/or treating autoimmune disorders, cancer, transplant rejection, and other IL-6-associated diseases, as well as ... | 02/16/2012 |
| 20120039841 | T-Helper Cell Type 17 Lineage-Specific Adjuvants, Compositions and Methods The present invention relates to compositions and methods for the modulation of TN 17 responses. The invention provides compositions for the induction of TN 17 responses containing a TLR agonist and an apoptotic cell-associated agent or containing ... | 02/16/2012 |
| 20120039800 | Platinum Acridine Anti-Cancer Compounds And Methods Thereof Acridine containing cisplatin compounds are disclosed that show greater efficacy against cancer than other cisplatin compounds.... | 02/16/2012 |
| 20120039980 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional grou... | 02/16/2012 |
| 20120034184 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION The present invention relates to the use of nucleoside derivatives of formula I
| 02/09/2012 |
| 20120027770 | NOVEL CELL AND THERAPEUTICAL AND DIAGNOSTICAL METHODS BASED THEREON The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to... | 02/02/2012 |
| 20120027808 | NICOTINE IMMUNONANOTHERAPEUTICS The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that compr... | 02/02/2012 |
| 20120027720 | PEPTIDE CONJUGATES The present invention provides novel peptide conjugates. Peptide conjugates of the invention can be used as therapeutic agents. Peptide conjugates invention may also be used to deliver one or more additional active agents. The present invention also provides methods for... | 02/02/2012 |
| 20120021036 | COMPOSITE NANOSTRUCTURES AND METHODS FOR MAKING AND USING THEM The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartme... | 01/26/2012 |
